<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618890</url>
  </required_header>
  <id_info>
    <org_study_id>LUMC-40226</org_study_id>
    <nct_id>NCT01618890</nct_id>
  </id_info>
  <brief_title>Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding</brief_title>
  <acronym>Porthos</acronym>
  <official_title>A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haga Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis:&#xD;
&#xD;
      Hepatic venous pressure gradient (HVPG)-directed primary prophylaxis with nonselective&#xD;
      beta-blocker therapy (NSBB) leads to a reduction in first variceal bleeding episodes and is&#xD;
      cost-effective in the long term.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided&#xD;
      by the hemodynamic response as determined by the difference in HVPG before and after starting&#xD;
      oral NSBB therapy, to standard heart rate-guided NSBB therapy in patients with esophageal&#xD;
      varices due to liver cirrhosis without a history of esophageal variceal hemorrhage.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      First variceal bleeding episodes occurring within the first two years.&#xD;
&#xD;
      Secondary study parameters/outcome of the study:&#xD;
&#xD;
        -  Mortality&#xD;
&#xD;
        -  Occurrence of other cirrhosis-related complications&#xD;
&#xD;
        -  Occurrence of hepatocellular carcinoma&#xD;
&#xD;
        -  Costs of treatments&#xD;
&#xD;
        -  Adverse effects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of the study:&#xD;
&#xD;
      About 50% of cirrhotic patients who use nonselective beta-blockers (NSBB) for primary&#xD;
      prevention of variceal bleeding do not reach target hemodynamic response, defined as HVPG &lt;&#xD;
      12 mmHg or a &gt; 20% decrease in HVPG from baseline. These so-called hemodynamic nonresponding&#xD;
      patients have significantly higher rate of first esophageal variceal hemorrhage as compared&#xD;
      to patients who do respond to NSBB.&#xD;
&#xD;
      International institutions that publish guidelines differ in their recommendations concerning&#xD;
      HVPG monitoring. As a result, practice currently varies widely.&#xD;
&#xD;
      The investigators hypothesize that HVPG-directed primary prophylaxis leads to a reduction in&#xD;
      first variceal bleeding episodes and is cost-effective in the long term.&#xD;
&#xD;
      Objective of the study:&#xD;
&#xD;
      To determine cost-effectiveness of hepatic venous pressure gradient (HVPG)-guided&#xD;
      nonselective beta-blocker therapy as compared to standard heart rate-guided beta-blocker&#xD;
      therapy in the primary prevention of esophageal variceal bleeding in cirrhotic patients.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided&#xD;
      by the hemodynamic response as determined by the difference in HVPG before and after starting&#xD;
      oral nonselective beta-blockers, to standard heart rate-guided nonselective beta-blocker&#xD;
      therapy in patients with esophageal varices due to liver cirrhosis.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Patients with liver cirrhosis and large (&gt;5 mm) esophageal varices without a history of&#xD;
      esophageal variceal hemorrhage.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      -In HVPG-group: Perform baseline HVPG measurement, then start propranolol 20 mg orally twice&#xD;
      daily (BID), increase the dose stepwise with 3 days interval to decrease the heart rate to&#xD;
      maximum tolerated dose. After 4 weeks a second HVPG is performed.&#xD;
&#xD;
      In hemodynamic responders (who reach target decrease in HVPG) NSBB are continued until end of&#xD;
      follow-up.&#xD;
&#xD;
      In hemodynamic nonresponders (who do not reach target decrease in HVPG), NSBB are continued&#xD;
      and repeated endoscopic band ligation is performed with 2-4 weeks interval until complete&#xD;
      obliteration of large varices.&#xD;
&#xD;
      -In control group: Start propranolol 20 mg BID, increase the dose stepwise with 3 days&#xD;
      interval to maximum heart rate-guided tolerated dose.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      First variceal bleeding episodes occurring within the first two years.&#xD;
&#xD;
      Secondary study parameters/outcome of the study:&#xD;
&#xD;
      Mortality Occurrence of other cirrhosis-related complications Occurrence of hepatocellular&#xD;
      carcinoma Costs of treatments Adverse effects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First variceal bleeding episodes</measure>
    <time_frame>two years of follow-up</time_frame>
    <description>First variceal bleeding episodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>two years</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of other cirrhosis-related complications</measure>
    <time_frame>two years</time_frame>
    <description>ascites spontaneous bacterial peritonitis hepatic encephalopathy hepatorenal syndrome hepatocellular carcinoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of treatments</measure>
    <time_frame>two years</time_frame>
    <description>Costs of treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>two years</time_frame>
    <description>Adverse effects associated with NSBB therapy, endoscopic band ligation, hepatic venous pressure gradient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Acute Bleeding Esophageal Varices</condition>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>HVPG-propranolol arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A baseline hepatic venous pressure gradient measurement (HVPG measurement) is performed in day-care setting. After this procedure propranolol is started at 20 mg BID. with dose escalation as described in the propranolol arm.&#xD;
A second HVPG measurement is performed at 4 weeks after adequate propranolol therapy. In patients who reach target HVPG reduction (responders), propranolol is continued at the same dose without routine control endoscopy. In patients who do not reach target HVPG reduction (nonresponders), endoscopic band ligation is performed in day-care setting with intervals of 2-4 weeks until complete obliteration of varices. Follow-up endoscopy with 6 months interval is performed to detect and treat recurrent large varices.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propranolol arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Propranolol start 20 mg BID. orally with dose escalation based on heart frequency (HF) with 3-days interval to the maximum tolerated dose. No routine control endoscopy is required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hepatic venous pressure gradient measurement</intervention_name>
    <description>Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.&#xD;
In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.&#xD;
In hemodynamic responders (HVPG second measurement&lt; 12 mmHg or &gt;20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up.</description>
    <arm_group_label>HVPG-propranolol arm</arm_group_label>
    <other_name>Hepatic venous pressure measurement</other_name>
    <other_name>Endoscopic variceal band ligation</other_name>
    <other_name>Propranolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with liver cirrhosis Large (≥5 mm) esophageal varices&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of esophageal variceal hemorrhage&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Contraindications to beta-blocker therapy&#xD;
&#xD;
          -  Esophageal varices in the absence of liver cirrhosis&#xD;
&#xD;
          -  Intermediate, advanced or terminal stage hepatocellular carcinoma (BCLC stage B, C or&#xD;
             D)&#xD;
&#xD;
          -  Refractory ascites&#xD;
&#xD;
          -  Hepatorenal syndrome&#xD;
&#xD;
          -  Prior treatment or prophylaxis for esophageal varices or varices bleeding (propranolol&#xD;
             use, TIPS, endoscopic banding ligation, endoscopic sclerotherapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minneke Coenraad, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minneke Coenraad, Dr.</last_name>
    <phone>+31-71-5269111</phone>
    <phone_ext>*9127</phone_ext>
    <email>m.j.coenraad@lumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerpen</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Vanwolleghem</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik Nevens, Prof. dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Beuers, Prof.dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Free University Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin van Nieuwkerk, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minneke Coenraad, Dr.</last_name>
      <phone>+31-71-5269111</phone>
      <phone_ext>99127</phone_ext>
      <email>m.j.coenraad@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Nicolaï, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 11, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. M.J.Coenraad</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Prevention</keyword>
  <keyword>Esophageal variceal bleeding</keyword>
  <keyword>Hepatic Venous Pressure Gradient</keyword>
  <keyword>Betablocker therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

